全文获取类型
收费全文 | 11730篇 |
免费 | 751篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 304篇 |
儿科学 | 302篇 |
妇产科学 | 316篇 |
基础医学 | 1675篇 |
口腔科学 | 426篇 |
临床医学 | 1009篇 |
内科学 | 2748篇 |
皮肤病学 | 207篇 |
神经病学 | 1309篇 |
特种医学 | 241篇 |
外科学 | 1101篇 |
综合类 | 44篇 |
一般理论 | 5篇 |
预防医学 | 702篇 |
眼科学 | 137篇 |
药学 | 727篇 |
中国医学 | 36篇 |
肿瘤学 | 1246篇 |
出版年
2024年 | 21篇 |
2023年 | 123篇 |
2022年 | 286篇 |
2021年 | 432篇 |
2020年 | 281篇 |
2019年 | 330篇 |
2018年 | 370篇 |
2017年 | 301篇 |
2016年 | 357篇 |
2015年 | 382篇 |
2014年 | 521篇 |
2013年 | 629篇 |
2012年 | 970篇 |
2011年 | 1079篇 |
2010年 | 536篇 |
2009年 | 475篇 |
2008年 | 815篇 |
2007年 | 753篇 |
2006年 | 666篇 |
2005年 | 691篇 |
2004年 | 626篇 |
2003年 | 577篇 |
2002年 | 509篇 |
2001年 | 85篇 |
2000年 | 72篇 |
1999年 | 76篇 |
1998年 | 98篇 |
1997年 | 65篇 |
1996年 | 50篇 |
1995年 | 50篇 |
1994年 | 34篇 |
1993年 | 37篇 |
1992年 | 31篇 |
1991年 | 21篇 |
1990年 | 13篇 |
1989年 | 19篇 |
1988年 | 14篇 |
1986年 | 16篇 |
1985年 | 11篇 |
1984年 | 12篇 |
1983年 | 6篇 |
1982年 | 7篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1974年 | 9篇 |
1973年 | 7篇 |
1972年 | 9篇 |
1971年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice 总被引:1,自引:0,他引:1
Ku CH White KE Dei Cas A Hayward A Webster Z Bilous R Marshall S Viberti G Gnudi L 《Diabetes》2008,57(10):2824-2833
OBJECTIVE—Podocyte-specific, doxycycline (DOX)-inducible overexpression of soluble vascular endothelial growth factor (VEGF) receptor-1 (sFlt-1) in adult mice was used to investigate the role of the VEGF-A/VEGF receptor (VEGFR) system in diabetic glomerulopathy.RESEARCH DESIGN AND METHODS—We studied nondiabetic and diabetic transgenic mice and wild-type controls treated with vehicle (VEH) or DOX for 10 weeks. Glycemia was measured by a glucose-oxidase method and blood pressure by a noninvasive technique. sFlt-1, VEGF-A, VEGFR2, and nephrin protein expression in renal cortex were determined by Western immunoblotting; urine sFlt-1, urine free VEGF-A, and albuminuria by enzyme-linked immunosorbent assay; glomerular ultrastructure by electron microscopy; and VEGFR1 and VEGFR2 cellular localization with Immunogold techniques.RESULTS—Nondiabetic DOX-treated transgenic mice showed a twofold increase in cortex sFlt-1 expression and a fourfold increase in sFlt-1 urine excretion (P < 0.001). Urine free VEGF-A was decreased by 50%, and cortex VEGF-A expression was upregulated by 30% (P < 0.04). VEGFR2 expression was unchanged, whereas its activation was reduced in DOX-treated transgenic mice (P < 0.02). Albuminuria and glomerular morphology were similar among groups. DOX-treated transgenic diabetic mice showed a 60% increase in 24-h urine sFlt-1 excretion and an ∼70% decrease in urine free VEGF-A compared with VEH-treated diabetic mice (P < 0.04) and had lower urine albumin excretion at 10 weeks than VEH-treated diabetic (d) mice: d-VEH vs. d-DOX, geometric mean (95% CI), 117.5 (69–199) vs. 43 (26.8–69) μg/24 h (P = 0.003). Diabetes-induced mesangial expansion, glomerular basement membrane thickening, podocyte foot-process fusion, and transforming growth factor-β1 expression were ameliorated in DOX-treated diabetic animals (P < 0.05). Diabetes-induced VEGF-A and nephrin expression were not affected in DOX-treated mice.CONCLUSIONS—Podocyte-specific sFlt-1 overexpression ameliorates diabetic glomerular injury, implicating VEGF-A in the pathogenesis of this complication.Vascular endothelial growth factor (VEGF)-A is constitutively expressed in glomerular visceral cells (podocytes). Paracrine VEGF-A signaling occurs between podocytes and adjacent endothelial and mesangial cells, which express VEGF receptors (VEGFRs) 1 and 2 (1–3), and both autocrine and paracrine signaling may occur in podocytes themselves (4).VEGF-A has been implicated in the regulation of glomerular barrier properties to protein filtration. In normal animals (5,6) and in cancer patients (7), inhibition of VEGF-A results in proteinuria; while in proteinuric conditions, which are associated with glomerular VEGF-A upregulation such as diabetes, systemic inhibition of VEGF ameliorates albuminuria (8–10). This evidence suggests that a tight regulation of VEGF-A expression level is required to maintain the physiological permselective properties of the glomerular filter.The results of previous studies conducted using either VEGF gene targeting techniques (5) or by administration of inhibitory agents of the VEGF/VEGFR system such as antibodies (6,8,9) or chemicals (10) may have been affected by potential interference with animal organ development and lack of tissue specificity in the mechanisms of action of systemic inhibitors. Soluble VEGF receptor-1 (sFlt-1), a splice variant of the VEGFR1, lacks the transmembrane and complete intracellular tyrosine kinase domain of VEGFR1 but binds to VEGF with the same affinity and specificity as that of the full-length receptor (11,12) and has potent and selective VEGF inhibitory action (11). sFlt-1 acts in two major ways: it can sequester VEGF competing for its binding to the VEGF receptors or can form heterodimers with the extracellular region of the membrane spanning VEGFR1 and VEGFR2, thus inhibiting the activation of downstream signaling pathways (11,12).To target the action of the podocyte-expressed VEGF-A, we developed a transgenic mouse model to overexpress sFlt-1 specifically at the podocyte level with an inducible expression system that is induced only after complete development, in the adult animal, by the administration of doxycycline (Tet-on). The aim of this study was to investigate the role of VEGF-A upregulation in the pathogenesis of diabetic glomerulopathy by locally inhibiting podocyte-expressed VEGF-A activity. 相似文献
992.
993.
It is known that melanoma develops as a consequence of multifactorial alterations. To date several studies indicate the effective implication of p16 as a tumor suppressor gene with a major role in either the development or progression of human melanoma. Deregulation of melanoma cell growth has been widely associated with mutations in the p16-cyclin D/cdk4-pRb pathway. Recently anticancer therapies are focused on restoration of p16 CDK inhibitory function and other proteins unregulated in melanoma cell cycle pathway (e.g., c-myc, p27). A combined strategy for restoration of normal homeostasis in the melanoma skin with targeted delivery of apoptosis-inducing agents does not seems to be far obtained. New class of antitumoral agents are emerging: histone deacetylase (HDAC) inhibitors have attracted much interest because of their ability to arrest cell growth, induce cell differentiation, and in some cases, induce apoptosis of cancer cells. Recently, attention has been focused on the ability of HDAC inhibitors to induce perturbation in cell cycle regulatory protein (e.g., p21(CIP1)) and down-regulation of survival signalling pathway. In the present study, we have examined the effect of valproic acid (VPA) on M14 human melanoma cell line. Here we observed that VPA induces cell cycle arrest and apoptosis sensitising melanoma cells to cis-platin and etoposide treatment. IC(50) dose (2.99 mM) of VPA was able to induce G(1) arrest (up to 75%) in association with upregulation of p16, p21 and cyclin-D1 related to Rb ipo-phosphorilation. In addition VPA activated apoptosis (50%) in M14 cells, when given alone or in combination with antitumoral agents. The ability of valproic acid to reestablished the G(1) pathway in melanoma cells suggests a potential application of VPA in melanoma therapeutic protocols. 相似文献
994.
Rutz HP Weber DC Sugahara S Timmermann B Lomax AJ Bolsi A Pedroni E Coray A Jermann M Goitein G 《International journal of radiation oncology, biology, physics》2007,67(2):512-520
PURPOSE: To evaluate the use of postoperative proton therapy (PT) in extracranial chordoma. PATIENTS AND METHODS: Twenty-six patients were treated. Gross total resection was achieved in 18 patients. Nine patients had cervical, 2 had thoracic, 8 had lumbar, and 7 had sacro-coccygeal chordomas. Thirteen patients had implants. PT was administered after function-preserving surgery, using a gantry and spot scanning, without or with intensity modulation (IMPT; 6 patients), and/or photon-based radiotherapy (RT, 6 patients). Median total dose was 72 cobalt Gray equivalent (CGE; range, 59.4-74.4), with means of 70.5 and 73.2 CGE for patients with and without implants. Median follow-up time was 35 months (range, 13-73 months). Adverse events were scored using the Common Terminology Criteria for Adverse Events grading system (version 3.0). RESULTS: At 3 years, actuarial overall survival (OS) and progression-free survival (PFS) rates were 84% and 77%, respectively. One patient each died of local failure (LF), distant failure (DF), suicide, and secondary tumor. We observed 5 LFs and 3 DFs; 3-year LF-free and DF-free survival rates were 86%. We observed four radiation-induced late adverse events (Grade 2 sensory neuropathy; Grade 3 subcutaneous necrosis, and osteonecrosis; and Grade 5 secondary cancer). In univariate analysis, implants were associated with LF (p = 0.034). Gross residual tumor above 30 mL was negatively associated with OS (p = 0.013) and PFS (p = 0.025). CONCLUSIONS: Postoperative PT for extracranial chordomas delivered with spot scanning offers high local control rates. Toxicity was acceptable. Implants were significantly associated with LF. Residual tumor above 30 mL impacted negatively on OS and PFS. 相似文献
995.
Carlini P Michelotti A Ferretti G Ricci S Giannarelli D Pellegrini M Cresti N Di Cosimo S Bria E Papaldo P Fabi A Ruggeri EM Milella M Alimonti A Salesi N Cognetti F 《Cancer investigation》2007,25(2):102-105
OBJECTIVES:The aromatase inhibitors Anastrozole, Letrozole (type 2 nonsteroidal aromatase inhibitors: n-SAI) and Exemestane (type 1 steroidal aromatase inactivator) are used respectively as first- and second-line hormonal therapy in postmenopausal metastatic breast cancer women. Few clinical data are published on the sequential use of different classes of aromatase inhibitors. METHODS: We report an analysis on 30 postmenopausal metastatic breast cancer women treated between January 2000 and May 2002 in 2 Italian Oncology Institutions with the hormonal sequence n-SAI (Anastrozole, Letrozole) --> Exemestane. RESULTS: When receiving n-SAI (Anastrozole 8 patients and Letrozole 22 patients), 1 out of 30 women achieved a partial response, 20 of 30 patients no change (NC) > or =6 months. The analysis of the entire population treated with Exemestane showed an overall clinical benefit (CB) of 46.6 percent (14/30) with a median duration of 12 months (95%CI 6-25) and a median time to progression (TTP) of 4 months (95%CI 1-25). CONCLUSIONS: These data confirm a partial lack of cross-resistance between n-SAI --> Exemestane given in sequence. 相似文献
996.
Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer 总被引:3,自引:0,他引:3
Metro G Sperduti I Russillo M Milella M Cognetti F Fabi A 《The oncologist》2007,12(12):1467-9; author reply 1469-71
997.
Sitbon O Manes A Jais X Pallazini M Humbert M Presotto L Paillette Ld Zaccardelli D Davis G Jeffs R Simonneau G Galie N 《Journal of cardiovascular pharmacology》2007,49(1):1-5
Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension (PAH); however, chemical instability and a short half-life have caused limitations in its use. The chemically stable prostacyclin analogue treprostinil has a longer half-life, and improves hemodynamics and signs/symptoms of PAH. This study investigated the feasibility of transitioning patients with PAH from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol. Twelve PAH patients were enrolled in a 12 week prospective open label study. Patients were switched from intravenous epoprostenol to intravenous treprostinil (1:1 ng/kg/min) by a direct switch of the medication reservoir from epoprostenol to treprostinil. The dose of treprostinil was adjusted throughout the study to achieve a 2-fold increase of treprostinil compared with the baseline epoprostenol dose. Rapid transition to treprostinil was achieved without serious adverse events and, baseline clinical status was maintained over 12 weeks. The mean baseline epoprostenol dose was 28 +/- 14 ng/kg/min. At week 12, the mean treprostinil dose was 62 +/- 30 ng/kg/min. All patients reported less prostacyclin-related side effects with treprostinil and remained on treprostinil after study completion. Selected patients with PAH can be safely transitioned from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol. 相似文献
998.
Zia-Amirhosseini P Hurd DD Salfi M Cheah TC Aycock J Cesano A 《Pharmacotherapy》2007,27(10):1353-1360
STUDY OBJECTIVE: To assess the pharmacokinetic profile of palifermin after intravenous dosing with either a collapsed dose of 180 microg/kg/day for 1 day or a standard dose of 60 microg/kg/day for 3 days, before and after myeloablative chemoradiotherapy and peripheral blood progenitor cell (PBPC) transplantation. DESIGN: Prospective, open-label pharmacokinetic study. SETTING: University-affiliated hematology and oncology center. PATIENTS: Twenty-five adult patients with hematologic malignancies receiving myeloablative therapy; 13 were in the standard-dose group, and 12 were in the collapsed-dose group. INTERVENTION: Patients received total-body irradiation (study days -8 to -5), etoposide (day -4), cyclophosphamide (day -2), and PBPC transplantation (day 0). Standard-dose palifermin was administered on days -11, -10, -9, 0, 1, and 2; collapsed-dose palifermin was administered on days -11 and 0. MEASUREMENTS AND MAIN RESULTS: Baseline demographic and clinical characteristics were recorded. Blood samples were obtained for pharmacokinetic assessment, presence of palifermin antibodies, and routine chemistry and hematology panels. Adverse events were documented daily. For both dosing groups, palifermin concentrations declined rapidly (>or= 98%) in the first 30 minutes and increased slightly between 1 and 4 hours after dosing, with a terminal decay phase. For standard-dose palifermin, mean values for area under the serum concentration-time curve (AUC) were within 15% between doses 1 and 3 and within 1% between doses 1 and 4. For collapsed-dose palifermin, mean AUC values and other pharmacokinetic parameters were within 2% between doses 1 and 2. Mean AUC on days -11 and 0 were approximately 4-fold higher for collapseddose palifermin than for standard-dose palifermin. Both dosing regimens were well tolerated. CONCLUSIONS: Our results were consistent with approximately dose-linear pharmacokinetics for the two dosing regimens, with no observed accumulation. A randomized, controlled study is warranted to assess the safety and efficacy of collapsed-dose palifermin, which may provide a more convenient administration schedule. 相似文献
999.
Federico Migliore MD PhD FESC FEHRA Raimondo Pittorru MD Pietro Bernardo Dall'Aglio MD Manuel De Lazzari MD Giovanni Rovaris MD Elena Piazzi MD Alessia Dentico CCP Alessandra Ferrieri CCP Giuseppe D'Angelo MD Alessandra Marzi MD Basma El Sawaf CCP Emanuele Bertaglia MD PhD Sabino Iliceto MD Gino Gerosa MD Vincenzo Tarzia MD PhD Domenico Carretta MD Patrizio Mazzone MD 《Journal of cardiovascular electrophysiology》2023,34(3):728-737
1000.
Maura Argenziano Chiara Tortora Alessandra Di Paola Elvira Pota Martina Di Martino Daniela Di Pinto Caterina Di Leva Francesca Rossi 《Oncotarget》2021,12(14):1377
Pediatric acute myeloid leukemia (AML) represents 20% of total childhood leukemia diagnoses and is characterized by poor prognosis with a long-term survival rate around the 50%, when patients are properly treated. The standard treatment for pediatric AML currently consists in a combination of cytarabine (Ara-C) and antracycline. Iron plays an important role in cancer development and progression. Targeting iron and its metabolism mediators could be a novel therapeutic strategy in cancer.Deferasirox (DFX) inhibits cancer cell proliferation and its use as an antiblastic drug could be suggested. Eltrombopag (ELT), a thrombopoietin receptor agonist used in immunethrombocytopenia, shows anticancer properties related to its emerging iron chelating properties. We compare the anticancer effect of classically used cytarabine with DFX and ELT effects in a pediatric AML cell line, THP-1, in order to identify innovative and more effective therapeutic strategies. ELT and DFX reduce intracellular iron concentration by inhibiting its uptake and by promoting its release. In particular, even though further investigations are needed to better understand the extact underlying action mechanisms, we demonstrated that ELT improves cytarabine antineoplastic activity in pediatric AML cell line. 相似文献